Epclusa

Phase 2

MERCK (MRK)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Lung Diseases

View Full Landscape

Drug Information

Target Indication

Lung Diseases

Clinical Trial

NCT03724149

Last updated: 9/5/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA7/6/2016

Epclusa

Epclusa is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients 3 years of age and older (see sections 4.2, 4.4 and 5.1).

Accelerated

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

MRK

MERCK

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Vericiguat tabletPhase 3

Heart Failure

Pegylated interferon alfa-2b (SCH 54031)Phase 3

Hepatitis C, Chronic

ElbasvirPhase 3

Hepatitis C

V260Phase 3

Rotavirus Gastroenteritis

MK-8591APhase 3

HIV-1 Infection

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts